Crystallization industrial process complete guide

Industrial crystallisation process — definition: Complete end-to-end platform for scaled-up purification of pharmaceutical and chemical APIs via controlled crystallisation, including process development, scale-up validation, polymorph control, crystal characterisation and GMP batch manufacturing, in accordance with FDA 21 CFR Part 211, ICH Q6A and GMP Annex 1 (2022), with a focus on product quality, cost-effectiveness and process robustness.

Key points

Crystallisation pipeline: method development (solvent screening, temperature profile) → pilot scale-up → process validation (3 batches) → production scale
Standard: GMP Annex 1 (2022), FDA 21 CFR Part 211, ICH Q6A (product specs), ICH Q3C (solvent guideline), USP 921 (crystal growth)
HECHT product: End-to-End Crystallization Platform + Multi-Scale Reactors + Integrated Analytics + GMP Documentation
Application: pharmaceutical API purification, chemical specialties, polymorph selection, high-purity products
Efficiency: 80–95% product recovery, >99% crystal purity, 50–80% cost saving vs. other purification methods

This complete guide describes crystallisation end-to-end: method screening, scale-up strategy, process validation and production optimisation. Test & Trial Centre in Pörnbach available for development support; see our integrated crystallisation platforms and API purification services.

FAQ — Industrial crystallisation process

How do you choose the best solvent for crystallisation development?

Screening: 10–20 solvents based on solubility-temperature profile (high at high T, low when cold). Preference: solvent with >2× solubility difference between room temperature and 0°C. GMP suitability: aim for ICH Q3C class 3 (low toxicity). Cost-effectiveness: recycling capacity >80%. Pilot screening: typically identifies 3–5 favoured solvents.

What are the main scale-up risks from 1L to 100L?

Risks: nucleation inhomogeneity (seed distribution), temperature gradients (large volumes), mixing ineffectiveness, contamination (handling). Mitigation: geometric similarity (height/diameter ratio), seed strategy (equal amount/volume), temperature profile verification (thermocouples). Validation: typically 3 consecutive batches at production scale.

How much time and cost for crystallisation process development to GMP?

Development: 2–4 months (method screening, 10–20 runs). Scale-up: 3–6 months (IQ/OQ/PQ, 3 validation batches). GMP dossier: 8–12 weeks. Total: 6–12 months. Cost: €100K–€300K (labour, analytics, small-scale apparatus). HECHT accelerates this via PAT and computational modelling.

How does cooling rate affect crystal size and purity?

Slow, controlled cooling produces larger, purer crystals because impurities have time to remain in the mother liquor rather than becoming trapped in the crystal lattice. Rapid cooling produces finer crystals with a larger specific surface area, which can complicate filtration but does increase yield per cycle. The right balance depends on the desired particle size for downstream processing such as filtration and drying.

Author: Joost van Velzen, Managing Director Hecht Technology B.V.